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Summary.-The prevalence of high levels of circulating ACTH-like immunoactivity
was determined in 134 patients with lung cancer, using reference ranges from 52
age- and sex-matched patients with non-malignant lung disease. Two studies used
ACTH radioimmunoassays with different specificities. Study A used an unextracted
plasma or serum assay for total ACTH immunoactivity. High serum ACTH levels
occurred in 24% of patients with small-cell carcinoma and 3O% of patients with non-
small-cell cancer. In patients with small-cell carcinoma, levels were high in 120,,
with limited disease and 32% with extensive disease.
Study B used an ACTH assay after plasma extraction by porous glass, which
measured mainly regular 1-39 ACTH. Here no lung-cancer patient had levels above
the reference range, suggesting that the high levels in Study A may be due to plasma
ACTH components which are poorly extracted by porous glass.
It is concluded that high circulating ACTH immunoactivity occurs in a minority
of patients with lung cancer, particularly those with extensive small-cell carcinoma.
Indirect evidence suggests that the high ACTH levels detected with assays for
total ACTH are due to molecular forms otherthan 1-39ACTH,probably high-mol.-wt
species.
THERE IS NOW considerable evidence
that production of ACTH and related
peptides occurs commonly in lung cancer,
particularly the small-cell variety, though
the overt ectopic ACTH syndrome is
much less prevalent (Ratcliffe & Podmore,
1980). Several authors have assessed the
prevalence of circulating ACTH levels
in lung-cancer patients, in an attempt to
evaluate the potential clinical value of
the ACTH assay as a tumour marker in
diagnosis, prognosis and monitoring of
lung cancer. No consensus has emerged
from these studies: some authors have
described high plasma ACTH levels in
miiost patients with lung cancer of all
histological types, when compared to
levels in normal controls (Ayvazian et al.,
1975: WVolfsen & Odell, 1979). High
levels were also found in up to one-third
of patients with non-malignant lung
disease (Gewirtz & Yalow, 1974). In
contrast, others have reported high
circulating ACTH levels in only a minority
of lung-cancer patients, most of whom
had small-cell tumours (Gropp et al.,
1980). However, these studies differed in
several potentially important ways, in-
cluding patient selection, stage of disease
and tumour histology, type of sample,
assay specificity and reference groups.
We have therefore attempted to define
more clearly the prevalence of raised
circulating ACTH-like immunoactivity in
lung cancer, by comparing levels in
patients with lung cancer of defined
histology and stage with those in an age-
and sex-matched reference group with
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non-malignant lung disease. Two types
of radioimmunoassay have been used:
an assay for "total" ACTH immuno-
activity in plasma or serum without
prior extraction of the hormone ("un-
extracted" assay) and assays for ACTH,
p - melanocyte - stimulating hormone
(3MSH) and lipotrophic hormone (LPH)
immunoactivities after hormone extrac-
tion from plasma ("extracted" assays).
METHODS
Patients studied (Table 1).-One hundred
and thirty-four patients with lung cancer
attending the outpatient department or
admitted to hospitals in Glasgow, U.K.,
and Marburg, F.R.G., during 1978 and 1979
were studied. The diagnosis of lung cancer
was confirmed by bronchial or pleural
biopsy, biopsy of enlarged lymph nodes or
other metastases, sputum cytology, or retro-
spectively at necropsy. Patients in whom
the tumour was confined to the hemithorax,
ipsilateral, mediastinal and cervical lymph
nodes were considered to have localized
disease. Tumour spread beyond these limits
was described as extensive. Tumours were
classified histologically as small-cell and non-
small-cell according to the WHO classifica-
tion, by pathologists in Glassgow- and
Marburg who were unaware of the clinical
details and laboratory findings.
The reference group comprised 52 patients
attending a Glasgow hospital with non-
malignant pulmonary disease who were
matched for age and sex with the GlasgoN
lung-cancer patients. None of the patients
or controls was taking corticosteroid or other
drugs known to affect ACTH secretion, and
none had overt Cushing's syndrome. Fifty-
two per cent of the control patients had been
regular cigarette smokers within 1 year of
the investigation.
Blood samples.-Ten-ml samples of venous
blood were taken between 09:00 and 10:00 h
into heparinized and/or plain tubes. The
heparinized blood was immediately centri-
fuged and the plain blood was allowed to
clot at room temperature. The plasma or
serum was snap-frozen in dry ice, and stored
at -20°C until assayed.
Assays.-Two studies were performed using
different radioimmunoassays (RIA):
Study A: Unextracted double-antibody RIA
for "total" ACTH immunoactivity.-Ninety-
three sera and 44 plasma samples from 113
patients with lung cancer were assayed.
Both serum and plasma samples were
assayed in 24 of these patients. In addition,
assays were performed on serum and plasma
samples from each of 30 patients with non-
malignant lung disease. This assay used
human 1-39 ACTH for iodination and
standardization (MRC 74/555) and an anti-
serum raised in rabbits against human
1-39 ACTH (kindly supplied by Dr L.
Husager, Medi-Lab, Denmark). When com-
pared to human 1-39 ACTH, this antiserum
cross-reacted 98% with 1-24 ACTH, but
showed no significant cross-reaction with
human 18-39 ACTH, human f and yLPH,
human flMSH, ,B-endorphin and leu- and
met-enkephalins. The ACTH assay was
performed as follows: 200 ,ul serum, plasma
or standard solution was incubated over-
night at 4°C with 200 pl saline/albumin
diluent, 100 ,A antiserum (final dilution
1:48,000 in EDTA containing phosphate
buffer) and 100 ,Iu 1251-ACTH ( 25 pg).
Carrier normal rabbit serum and donkey
anti-rabbit serum (100 ,ul each) were added
and incubated overnight at 4°C. After
TABLE I.- Clinical details ofpatients studied
Study A
Controls
20
23
62
45-85
73 Chronic bronchittis
40 Bronchopulmonary
infection
Asthma
Miscellaneous
r-
Lung cancer
21
18
66
53-82
Small-cell
Non-small-
eell
17
7
:1
:3
Study B
Controls
22
18
65
51-78
7 Chronic bronchitis
14 Bronchopulmonary
infection
Asthma
Miscellaneous
r
Total
Males (No.)
Mean age
(years)
Age range
Diagnosis
Lung cance
113
99
63
46-78
Small-cell
Non-small-
cell
14
3
1
4
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centrifugation and aspiration of the super-
natant, the bound fraction was counted. The
assay was validated by comparison of ACTH
values obtained with the unextracted assay
at a plasma dilution of 1:4 with those found
withthe N-terminal ACTH assay onextracted
plasma described below. A good correlation
between methods was found in 61 paired
samples from normal subjects and patients
with a wide range of non-malignant condi-
tions associated with abnormal ACTH status
(unextracted ACTH value=0-99 x extracted
ACTH value+7-33, r=0-960). The limit of
detection ofthe unextracted assay was 10-20
ng/l, and interassay coefficient of variation
was 16%.
Study B: Extracted RIA for ACTH,
"3MSH", and LPH immunoactivity.-Plasma
samples from 21 patients with lung cancer and
from 22 patients with non-malignant lung
disease were assayed for ACTH, "fMSH" and
LPH immunoactivity after prior extraction.
For each hormone, a 5ml plasma aliquot was
extracted with porous glass by the method
of Ratcliffe & Edwards (1971). This method
selects against high-mol-wt ACTH com-
ponents and C-terminal ACTH fragments
so that the extracted ACTH assay is rela-
tively specific for 1-39 ACTH.
The ACTH RIA was as described by
Rees et al. (1971) using iodinated human
1-39 ACTH as tracer, an antiserum directed
towards the biologically active 1-24 region
of the molecule, and standardized against
natural human ACTH (MRC 74/555). The
limit ofdetection was 10 ng/l.
"fMSH" immunoactivity was assayed by
the method of Gray & Ratcliffe (1979)
standardized with synthetic human ,BMSH
(Ciba) using an antiserum which cross-
reacts equally on a molar basis with human
PMSH, /3LPH and yLPH. There was no
cross-reaction with ACTH, its fragments or
endorphin or enkephalins. The limit of
detection was 10 ng/l.
LPH immunoactivity was assayed by
the method of Podmore (1979) using iodina-
ted human 3LPH and an antiserum which
cross-reacts equally on a molar basis with
human : and yLPH. There was no cross-
reaction with human fMSH, ACTH or its
fragments, f-endorphin cr enkephalins. The
assay was standardized against purified
human fLPH (Dr P. J. Lowry). The limit of
detection was 80 ng/l.
Statistical analysis of grouped data was by
the Mann Whitney U test. Where an
individual value was undetectable a figure of
half the formal limit of detection was
assumed.
RESULTS
ACTIH values in plasma compared to serum
In order to determine whether ACTH
levels differ in plasma and serum, both
plasma and serum samples were taken at
the same time from 30 control patients
and the values compared. For plasma
samples, the median value was between
20 and 30 ng/l and the absolute range was
< 20-73 ng/l. For serum samples, the
TABLE II.-Prevalence of high total-ACTH levels in serum and plasma in patients with
lung cancer
Plasma Serum
IA-
Lung cancer
Small-cell
,. Limited
Extensive
All cases
Non-small-cell
Limited
Extensive
All cases
All lung-cancer cases
*P < 0 01 vs controls.
tP < 0-001 Vs controls.
Total No.
6
12
18
20
6
26
44
No. > control range
(< 20-73 ng/l)
(%)
0 (0)
3 (25)
3 (17)
0 (0)
0 (0)
O (0)
3 (7)
Total No.
25
38
63
20
10
30
93
No. > control range
(< 20-50 ng/l)
(%)
3 (12)*
12 (32)t
15 (24)t
0 (0)
1 (10)
1 (3)
16 (17)t
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median value was < 20 ng/l and the
absolute range was < 20-50 ng/l.
It is concluded that plasma ACTH levels
are slightly higher than serum values.
In view of this, the subsequent prevalence
data in lung cancer patients in Study A
are related to the reference range obtained
in the appropriate type of sample: e.g.,
unextracted serum ACTH levels in lung
cancer patients are related to the control
range in unextracted serum.
Study A (total ACTH immunoactivity)
Table II summarizes the prevalence of
high total ACTH levels in plasma or
serum expressed in relation to the appro-
priate plasma or serum reference range.
The patterns are similar for plasma and
serum, though the smaller number of
plasma samples probably makes those
figures less reliable for the small cell
group. Serum ACTH levels were signifi-
cantly higher in patients with either
limited or extensive small-cell cancer
than in controls or non-small-cell cancer.
Likewise the prevalence of high serum
ACTH levels is much greater in patients
with small-cell than non-small-cell cancer
(24% vs 30o). Only 1 patient with non-
small-cell cancer had a high serum
ACTH level (55 ng/l). In the small-cell
group, high serum levels were related to
stage of disease, being - 25-fold more
frequent in patients with extensive disease.
However, even in patients with high
ACTH levels and small-cell cancer the
degree of abnormality was modest. Six
patients had levels > 100 ng/l, and only 1
had a level > 200 ng/l (250 ng/l).
TABLE III. Prevalence of high plasma
extractioi
Study B (extracted ACTH, ,8MSH andl
LPH immunoactivity
Table III summarizes the prevalence of
elevated ACTH, fMSH and LPH levels in
extracted plasma. In contrast to Study A,
the levels are uniformly within the
reference range, except for a single
patient with non-small-cell cancer with a
marginally high LPH (356 ng/l). Although
the number of patients is small, particu-
larly those with small-cell carcinoma,
these data confirm the low prevalence of
high levels of ACTH and related peptides
in lung cancer, and suggest that the
prevalence with the extracted ACTH
assay is much less than with the unlex-
tracted assay.
DISCUSSION
Our observations suggest that the
prevalence of high levels of ACTH im-
munoactivity in patients with lung cancer
is relatively low, is mainly associated
with extensive small-cell cancer, and is
apparently related to the specificity of
the ACTH assay. The prevalence is
similar to that reported by Gropp et al.
(1980), Hansen et al. (1980a) and Torstens-
son et al. (1980) but much lower than
described by Ayvazian et al. (1975),
Yalow et al. (1979) and Wolfsen & Odell
(1979) (Table IV). We have attempted
to analyse some of the factors which
mav account for these discrepancies.
Type and time of sampling
Comparison ofunextracted ACTH levels
in plasma and serum samples (Table II)
shows that levels are lower in serum than
levels of ACTH, /3MSH and LPH using
n methods
1\ISH (ng/l)
No.
> control
range
I Rainge No. (14-62)
13-51 7 0
16-49 14 0
13-51 2 ()
LPH (ng/l)
No.
> control
range
Rainge No. (< 80-341)
< 80-256 7 0
< 80-356 14 1
< 80-356 21 1
ACTH (ng/1)
Lung cancer
Small-cell
Non-small-cell
All cases
Ranige
< 10-34
< 10-35
< 10-35
No.
> control
i-ange
(< 10-73)
0
0
No.
7
14
21
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TABLE IV.-Prevalence of elevated ACTH concentrations in plasma and serumt of lung
cancer patients before treatment
Authors Patients
Gropp et al., 1980 Unselecte(d
Yalow et al., 1 979 Surgical nioui-
small-cell
Ayvazian et (tl.,
1975
Sample
and
metho(d
Plasma an(l
serum
tinextracte(l
P'lasma
unextracted
Unselected Plasma
tinextra(tedl
Hansen e al. Unselected Plasma
1980a small-cell tinextrac-te(d
Wolfsen & Odell,
1979
Torstenssoin et (d.,
1980
Unselecte(d Plasma
radiograplie Extracte(d
abnormality
Unse;lecte I'lasma
uinextrac-te(l
Reference
value
(ng/l)
Percentage prevalence
of patients with values
above reference value
Derivation Non-
of reference Small- small- All
value cell cell patients
80 Age- and sex-
matchect
normal
controls
150 Normal control
range.
Sampled, p.m.
150 Normal control
range.
Samplecl, p.m.
76 Mean+2 s.d. of
laboratory
controls
1(7 Mean + 2 s.d. of
normals and
patients withi
minor illness.
Sampled, a.m.
216 Upper limit of
absolute range
in benign
pulmonary
(lisease.
Sampled, p.m.
:() I() 19
72 72
0)M 72 88
29 29
74
17
plasma, possibly due to loss of immuno-
activity during clotting, since it is well
recognized that endogenous ACTH and
exogenous human 1-39 ACTH are un-
stable in whole blood (Besser et al.,
1971). However, comparison of plasma
or serum levels in lung-cancer patients
with their counterparts in control patients
gave similar prevalence figures, suggest-
ing that differences in sample handling
cannot account for large variations in
prevalence.
Our samples were taken in the morning,
when higher ACTH levels may be ex-
pected. Others have reported a high or
low prevalence irrespective of time of
sampling (Table IV).
Definition of reference range
Most previous studies have compared
values in lung-cancer patients with those
in normal subjects (either as absolute
reference ranges or 95%I confidence limits).
We consider that age- and sex-matched
patients with non-malignant lung disease
and comparable smoking histories form
a more appropriate reference group, since
lung cancer often occurs on a background
of other lung pathology. Immunoactive
ACTH has been described in bronchial
epithelium of a smoking dog with atypical
premalignant changes (Gewirtz & Yalow,
1974). Such changes are described in
heavy smokers who died of other disease
as well in the lungs oflung-cancer patients
(Auerbach et al., 1961). It is thus possible
that circulating ACTH may be increased
by concomitant epithelial changes as
well as by tumour secretion. In addition,
neuroendocrine activation in disease-in-
duced stress may enhance pituitary ACTHB
secretion. In support of this, Torstensson
et al. (1980) found higher ACTH levels
in patients with non-malignant lung
disease than in normal subjects.
However, the selection of control
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patients cannot explain the different pre-
valences, since higher or lower figures are
reported when normal subjects are used
as controls. Although the low prevalence
reported by Torstensson et al. (1980) may
be in part related to the high control
reference range, our reference range was
similar to what we have found in healthy
subjects. It is noteworthy that the highest
prevalence figures were in studies that
also reported much higher reference values
than the present study. This implies
differences in assay standardization and
specificity (vide infra).
Nature and extent of tumour
The ectopic ACTH syndrome is most
commonly due to small-cell carcinoma of
lung (Broder, 1979). Other histological
types of lung cancer rarely cause the
syndrome. The present Study A, and that
of Gropp et al. (1980), find a greater
prevalence of raised ACTH levels in
small-cell carcinoma, whereas Yalow et
al. (1979) report a high prevalence in
non-small-cell cancer. The latter is difficult
to reconcile with a tumour origin of
ACTH, since tumour-tissue concentra-
tions are usually very low or negative for
ACTH and related peptides in this
histological type. It therefore seems un-
likely that differences in tumour histology
can account for the variation in preva-
lence. Similarly, differences in degree of
tumour spread does not readily account
for the discrepancies. Yalow et al. (1979)
studied surgical cases with presumably
Stage I and II tumou-s, and Wolfsen &
Odell (1979) investigated patients with
peripheral coin lesions and other localized
radiographic abnormalities. In contrast,
our series contained patients with exten-
sive disease in whom circulating ACTH
levels might be expected to be higher.
Assay specificity
A major problem in comparing previous
reports is evaluation of assay specificity.
Tumour and plasma ACTH from patients
with ectopic ACTH syndrome, is hetero-
geneous, with a high but variable pro-
portion of high-mol.-wt species and frag-
ments (Ratter et al., 1980; Pullan et al.,
1980). Assay specificity with respect to
these components is uniformly poorly
defined, since purified materials are not
available for formal cross-reaction studies.
Most authors have employed assays which
detect the N-terminal portion of ACTH
and some, including our unextracted
assay cross-react to an unknown extent
with high-mol.-wt species.
Extraction by porous glass increases
the specificity towards 1-39 ACTH and
our finding of a reduced prevalence with
the extracted assay confirms the report
of Gewirtz & Yalow (1974) that high-
mol.-wt ACTH is a major component of
ACTH-producing lung tumours. The low
prevalence reported with a radioreceptor
assay which measures predominantly 1-39
ACTH (Wolfsen & Odell 1979) also
supports this contention. Against this,
these authors also reported a high pre-
valence using their extracted ACTH
assay which might be expected to select
against high-mol.-wt forms of ACTH.
Clearly, further work is required using
assays of defined specificities to all the
ACTH-like components in lung-cancer
plasma, as assay specificity seems likely
to be a major factor in accounting for
these discrepancies.
In conclusion, our results show that
high serum ACTH immunoactivity
occurs in less than 20% of patients with
lung cancer, but is commoner in extensive
small-cell cancer. ACTH assays thus
appear to have no value in screening
or diagnosis of lung cancer. However, in
patients with high ACTH levels, serial
measurements could be useful in assessing
response to treatment and in detecting
recurrence (Hansen et al., 1980b). Further
studies should devote attention to the
type of sample, selection of reference
group, tumour histology and spread.
However, we consider that definition of
the nature of circulating ACTH in lung
cancer, with development ofassays specific
for the tumour-related components, is a
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vital precondition for definitive evalua-
tion of ACTH levels in lung cancer.
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